Wyatt Christopher F. 4

What Happened

• Christopher F. Wyatt, SVP & Controller of HCA Healthcare, received a grant of 2,560 stock appreciation rights (SARs) on January 29, 2026. The award was recorded at $0.00 per unit (derivative award); no cash was exchanged at grant.
• This is an equity compensation award (not an open-market purchase or sale) and is typically part of executive pay rather than a direct market bet.

Key Details

• Transaction date: 2026-01-29; filing date: 2026-02-02 (filed within the Form 4 two-business-day window — timely).
• Transaction type/code: Award/Grant (A); derivative instrument (SARs).
• Number of SARs granted: 2,560; grant price reported as $0.00.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The SARs vest in four equal annual installments beginning January 29, 2027.

Context

• Stock appreciation rights (SARs) are a form of deferred compensation that pay the holder the increase in stock value from the grant date, often settled in shares or cash depending on plan terms. They do not represent immediate stock purchases or sales.
• Such grants are common as part of executive compensation and do not by themselves indicate the insider is buying or selling shares in the open market.